Thu.Jan 13, 2022

Remove category
article thumbnail

CMS “Splits the Baby” on Aduhelm—Medicare Coverage but Only with Evidence Development for Now

Health Law Advisor

In 2021, the FDA approved the first anti-amyloid monoclonal antibody drug, Aduhelm, which is intended to trigger a response by the patient’s own immune system that destroys the accumulation of amyloid plaques. The FDA’s determination does not mandate Medicare coverage for Aduhelm. What Happens Next?